Kwangdong introduces new drug candidate for pediatric myopia

The S.Korean company signed a contract with Zhaoke, a Hong Kong company that holds the rights for NVK002 in Asia

Kwangdong Pharmaceutical CEO Choi Seong-won (left) and Zhaoke CEO Li Xiaoyi
Kwangdong Pharmaceutical CEO Choi Seong-won (left) and Zhaoke CEO Li Xiaoyi
Ji-Hyun Lee 1
2023-03-27 15:03:49 bluesky@hankyung.com
Bio & Pharma

South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it has signed a contract with Hong Kong-based Zhaoke Ophthalmology Ltd. to introduce a new drug candidate for pediatric myopia called NVK002.

The drug was developed by the American pharmaceutical company Vyluma and is known to work on the central nervous system to expand the pupil.

Zhaoke holds the Asian regional rights to NVK002, and as part of the contract, Kwangdong Pharmaceutical will have exclusive sales rights for importing and distributing the drug in Korea.

CEO of Kwangdong Pharmaceutical, Choi Seong-won, said that the company expects NVK002 to play a key role in expanding its ophthalmic drug portfolio. He added that the company will focus on developing synergy with NVK002 through continuous research and development and introducing new drugs.

Li Xiaoyi, CEO of Zhaoke, expressed confidence that NVK002 will develop into an innovative drug that suppresses the progression of myopia in more pediatric and adolescent populations.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#Kwang Dong Pharmaceutical #Zhaoke Ophthalmology #NVK002 #Vyluma #korea kwangdong pharma #kwangdong zhaoke myopia

Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. The patent name is “Novel CTHRC1's specific antibody and use thereof."Following the PAUF (pancreatic adenocarcinoma up-regulated factor) neu

Lunit to export breast cancer detecting solutions to Hong Kong, Mongolia

Lunit to export breast cancer detecting solutions to Hong Kong, Mongolia

Lunit Insight MMG South Korea's AI-based medical imaging equipment firm Lunit will export AI breast cancer diagnosis solutions to large hospitals in Hong Kong and Mongolia.Lunit announced on Thursday that it has signed a contract to supply Lunit Insight MMG, an AI breast cancer screening soluti

JW Pharma applies for phase 3 trial in Taiwan for gout treatment

JW Pharma applies for phase 3 trial in Taiwan for gout treatment

JW Pharmaceutical headquarters JW Pharmaceutical announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, with the Taiwan Food and Drug Authority (TFDA).Epaminurad is an investigational oral uric acid transporter-1 (URAT1)

(* comment hide *}